1-BCPCAS# 34023-62-6 |
- CYT387 sulfate salt
Catalog No.:BCC1506
CAS No.:1056636-06-6
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Bardoxolone methyl
Catalog No.:BCC1400
CAS No.:218600-53-4
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 34023-62-6 | SDF | Download SDF |
| PubChem ID | 1370 | Appearance | Powder |
| Formula | C13H15NO3 | M.Wt | 233.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | 1,3-benzodioxol-5-yl(piperidin-1-yl)methanone | ||
| SMILES | C1CCN(CC1)C(=O)C2=CC3=C(C=C2)OCO3 | ||
| Standard InChIKey | BXBNADAPIHHXJQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C13H15NO3/c15-13(14-6-2-1-3-7-14)10-4-5-11-12(8-10)17-9-16-11/h4-5,8H,1-3,6-7,9H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | A centrally active selective potentiator of AMPA-mediated responses. Facilitates memory retention in rats. |
1-BCP Dilution Calculator
1-BCP Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.2869 mL | 21.4344 mL | 42.8688 mL | 85.7376 mL | 107.1719 mL |
| 5 mM | 0.8574 mL | 4.2869 mL | 8.5738 mL | 17.1475 mL | 21.4344 mL |
| 10 mM | 0.4287 mL | 2.1434 mL | 4.2869 mL | 8.5738 mL | 10.7172 mL |
| 50 mM | 0.0857 mL | 0.4287 mL | 0.8574 mL | 1.7148 mL | 2.1434 mL |
| 100 mM | 0.0429 mL | 0.2143 mL | 0.4287 mL | 0.8574 mL | 1.0717 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Vinorine
Catalog No.:BCN4649
CAS No.:34020-07-0
- Z-Ala-OSu
Catalog No.:BCC3057
CAS No.:3401-36-3
- 7-Oxodehydroabietinol
Catalog No.:BCN5265
CAS No.:33980-71-1
- Clivorine
Catalog No.:BCN2067
CAS No.:33979-15-6
- Pelargonidin-3-O-rutinosde chloride
Catalog No.:BCN3112
CAS No.:33978-17-5
- Triacetonamine hydrochloride
Catalog No.:BCN5264
CAS No.:33973-59-0
- Z-Leu-Osu
Catalog No.:BCC2592
CAS No.:3397-35-1
- H-D-Phe(4-Cl)-OMe.HCl
Catalog No.:BCC3174
CAS No.:33965-47-8
- Thalrugosidine
Catalog No.:BCN7785
CAS No.:33954-34-6
- Anamorelin Fumarate
Catalog No.:BCC1363
CAS No.:339539-92-3
- UBP1112
Catalog No.:BCC7033
CAS No.:339526-74-8
- Boc-Ile-Osu
Catalog No.:BCC2604
CAS No.:3392-08-3
- H-D-Phe-OtBu.HCl
Catalog No.:BCC3014
CAS No.:3403-25-6
- Auranofin
Catalog No.:BCC7952
CAS No.:34031-32-8
- SMIFH2
Catalog No.:BCC6162
CAS No.:340316-62-3
- Diclofensine hydrochloride
Catalog No.:BCC5541
CAS No.:34041-84-4
- 1,3-Bis(4,5-dihydro-2-oxazolyl)benzene
Catalog No.:BCC8417
CAS No.:34052-90-9
- 2-2'-(Hydroxytetracosanoylamino)-octadecane-1,3,4-triol tetraacetate
Catalog No.:BCN1454
CAS No.:340702-68-3
- Z-Pro-NH2
Catalog No.:BCC2753
CAS No.:34079-31-7
- (20S)-Protopanaxatriol
Catalog No.:BCN2705
CAS No.:34080-08-5
- Alpinumisoflavone
Catalog No.:BCN5266
CAS No.:34086-50-5
- 7-O-Methylbiochanin A
Catalog No.:BCN8212
CAS No.:34086-51-6
- Glycyrrhetic acid 3-O-mono-beta-D-glucuronide
Catalog No.:BCN1453
CAS No.:34096-83-8
- Araloside V
Catalog No.:BCN2466
CAS No.:340963-86-2
Aniracetam, 1-BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices.[Pubmed:10344525]
Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):272-9.
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic acid of the N-methyl-D-aspartate (NMDA)-evoked [3H]noradrenaline ([3H]NA) release from rat hippocampal slices. Aniracetam attenuated the kynurenate (100 microM) antagonism of the [3H]NA release elicited by 100 microM NMDA with high potency (EC50< or =0.1 microM). Cyclothiazide and 1-BCP were about 10 and 100 times less potent than aniracetam, respectively. The effect of aniracetam persisted in the presence of the AMPA receptor antagonist 6-nitro-7-sulphamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) added at 5 microM, a concentration that did not affect NMDA receptors; in contrast, NBQX reduced the effect of 1-BCP and abolished that of cyclothiazide. The AMPA-evoked release of [3H]NA from hippocampal slices or synaptosomes was enhanced by cyclothiazide, less potently by 1-BCP and weakly by aniracetam. High concentrations of kynurenate (1 mM) antagonized the AMPA-evoked [3H]NA release in slices; this antagonism was attenuated by 1 microM cyclothiazide and reversed to an enhancement of AMPA-evoked [3H]NA release by 10 microM of the drug, but was insensitive to 1-BCP or aniracetam. It is concluded that aniracetam exerts a dual effect on glutamatergic transmission: modulation of NMDA receptor function at nanomolar concentrations, and modulation of AMPA receptors at high micromolar concentrations. As to cyclothiazide and 1-BCP, our data concur with the idea that both compounds largely act through AMPA receptors, although an NMDA component may be involved in the effect of 1-BCP.
AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons.[Pubmed:9682831]
Neurosci Lett. 1998 Jun 19;249(2-3):119-22.
The benzoylpiperidine 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP), and related compounds, potentiate alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acidergic (AMPAergic) synaptic currents in central neurons, and improve performance of rodents and humans on learning and memory tasks. Their physiological actions are similar but not identical to thiazides, which also enhance AMPAergic synaptic responses and improve performance of rats in water-maze and passive-avoidance tests. Thiazides also dramatically increase AMPA receptor-mediated neuronal death in vitro and in vivo. Here it was evaluated whether 1-BCP potentiated AMPA receptor-mediated excitotoxicity in hippocampal neuron cultures. Glutamate + MK 801 (to block NMDA receptors) + 1 mM 1-BCP produced neuronal death that was reversed by 10 microM 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (NBQX), a selective AMPA receptor antagonist. 1-BCP and drugs with similar activities can facilitate AMPA receptor-mediated excitotoxicity.
1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices.[Pubmed:7542369]
Neuropharmacology. 1995 Feb;34(2):141-7.
It is now clear that the AMPA subtype of ionotropic glutamate receptors (iGluRs) undergoes a rapid desensitization in response to activation by AMPA receptor agonists. This desensitization is inhibited by compounds such as aniracetam and cyclothiazide, which act at a distinct site on the AMPA receptor complex. In particular, cyclothiazide greatly potentiates AMPA receptor-mediated depolarizing responses in the hippocampus. We have recently shown cyclothiazide also increases AMPA-induced release of [3H]norepinephrine ([3H]NE). More, recently, a benzamide compound, 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP), has been reported to enhance AMPA-induced currents and to facilitate memory retention in rats in a number of memory tasks. In this study, the effects of 1-BCP on excitatory amino acid agonist-induced [3H]NE release in rat hippocampal slices were determined. We report that 1-BCP, like cyclothiazide, selectively potentiates AMPA-induced [3H]NE release. However, cyclothiazide was more potent and efficacious than 1-BCP. Nevertheless, these data suggest a role for AMPA receptor-mediated enhancement of norepinephrine release as a mechanism of action for nootropic compounds such as 1-BCP.
Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion.[Pubmed:9286612]
Eur J Pharmacol. 1997 Aug 6;332(2):115-9.
Two allosteric alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor positive modulators, 1-(1,3-benzodioxol-5-ylcarbonyl)piperidine (1-BCP) and 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516), and the antipsychotic drug, haloperidol, were tested for their ability to inhibit hyperactivity induced by amphetamine and dizocilpine in mice. Haloperidol (0.03-1.0 mg/kg) and 1-BCP (20.0-120.0 mg/kg) attenuated hyperactivity induced by both amphetamine and dizocilpine, with higher potency against amphetamine. CX516 (30.0-170.0 mg/kg), however, failed to attenuate amphetamine- and dizocilpine-induced hyperactivity up to a dose which decreased spontaneous locomotor activity. These results indicate that AMPA receptor positive modulators may not be uniform with regard to their effects on dopamine-mediated behaviors and their antipsychotic potential.
A centrally active drug that modulates AMPA receptor gated currents.[Pubmed:7911064]
Brain Res. 1994 Feb 28;638(1-2):343-6.
Systemic administration of the drug 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP) has been reported to enhance monosynaptic responses in the hippocampus in vivo and to improve spatial and olfactory memory in rats. The drug's mechanism of action was investigated in the present study using membrane patches excised from cultured hippocampal slices. The decay time of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor mediated inward currents was greatly increased by 1-BCP in a concentration dependent and reversible fashion; peak current was also enhanced but to a lesser degree. In vitro slice experiments indicated that the drug has parallel effects on the field EPSP. It is concluded that 1-BCP is a centrally active modulator of the AMPA receptor.
